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Objective: The involvement of mediastinal lymph nodes is a very important prognostic factor in patients with
potentially resectable non–small cell lung cancer. Our aim in this study was to investigate the value of positron
emission tomographic–computed tomographic scanning in staging lung cancer, especially for mediastinal lymph
node evaluation, and to determine whether this could decrease the need for mediastinoscopy.
Methods: Seventy-eight patients with non–small cell lung cancer who were potential candidates for surgical re-
section and admitted to the thoracic surgery unit of our hospital from March 2006 to June 2008 joined this pro-
spective study. Positron emission tomographic–computed tomographic scanning was performed as part of the
prospective studies used to diagnose or stage the tumors. All 78 patients underwent tissue sampling of mediastinal
lymph nodes to compare these with imaging results. The diagnostic efficacy of the computed tomographic and
positron emission tomographic–computed tomographic scans compared with histopathologic findings were cal-
culated with sensitivity, specificity, positive and negative predictive values, and accuracy.
Results: Final histology was available on 397 lymph node stations (N1, N2, and N3) sampled from 78 patients
during mediastinoscopy or surgical intervention. Sensitivity, specificity, and positive and negative predictive
values of mediastinal lymph node involvement in patients undergoing thoracic computed tomographic scanning
were 45.4%, 80.5%, 27.7%, and 90%, respectively. The accuracy of computed tomographic scanning was
75.6%. The sensitivity, specificity, and positive and negative predictive values of mediastinal lymph node in-
volvement in patients undergoing positron emission tomographic–computed tomographic scanning were
81.8%, 89.5%, 56.2%, and 96.7%, respectively.
Conclusion: There is a need for mediastinoscopy in positron emission tomographic–computed tomographic
scanning–positive mediastinal lymph nodes, but it might not be necessary for positron emission tomographic–
computed tomographic scanning–negative lymph nodes.
General Thoracic Surgery Sxanlı et alThe involvement of mediastinal lymph nodes (MLNs) is an
important prognostic factor in patients with potentially re-
sectable non–small cell lung cancer (NSCLC). The appropri-
ate treatment of patients with NSCLC is based on accurate
staging. Various diagnostic tools are used for preoperative
staging of NSCLC, including chest radiography, computed
tomography (CT), magnetic resonance imaging, bronchos-
copy, thoracoscopy, mediastinoscopy, endobronchial and
endoscopic ultrasound-guided fine-needle aspiration biopsy,
and positron emission tomography (PET). PET scanning
with [18F]-2-fluoro-2-deoxy-D-glucose (FDG) imaging has
shown substantial promise during the past decade in helping
with the noninvasive preoperative staging of lung cancer.1 If
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critical. Resection is not considered in patients with lung can-
cer if there is MLN involvement. In these patients neoadju-
vant treatment is recommended before surgical intervention.2
Although PET scanning might accurately accomplish
lymph node staging in patients with lung cancer, mediastino-
scopy is often used for deciding unresectability pertaining to
the presence of N2/N3 disease. PET scanning is reported to
be more effective than CT scanning in lymph node staging;
however, efficacy increases further when results from both
methods are combined.3,4
Our aim in the present study was to evaluate the need for
such routine invasive sampling procedures in all cases to
confirm the findings of PET–CT scanning. The question
was whether PET–CT scanning was reliable for staging in




Seventy-eight consecutive patients with NSCLC who were potential can-
didates for surgical resection and were admitted to the thoracic surgery unit
of our hospital from March 2006 to June 2008 joined this prospective study.rgery c November 2009




CT ¼ computed tomography
EBUS–FNA ¼ endobronchial ultrasound-guided
fine-needle aspiration
EUS–FNA ¼ endoscopic ultrasound-guided
fine-needle aspiration
FDG ¼ [18F]-2-fluoro-2-deoxy-D-glucose
FNA ¼ fine-needle aspiration
MLN ¼ mediastinal lymph node
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
SUV ¼ standardized uptake value
After approval by the institution’s ethics committee, oral and written in-
formed consent was obtained from all the subjects. All patients were in-
cluded in this prospective study, excluding (1) patients with evidence of
metastatic disease, except for those with solitary brain or adrenal metastasis;
(2) patients who had not undergone PET–CT scanning as part of their pre-
operative evaluation or who had undergone FDG–PET scanning in another
center; and (3) patients with diabetes mellitus whose blood glucose levels
could not be controlled and brought to normal values. Because the patients
found to have N2 disease before neoadjuvant therapy were included, we did
not include patients receiving neoadjuvant treatment in this study. Complete
blood counts and blood chemistry tests, chest radiographs, thoracic CT
scans, PET-CT scans, pulmonary function tests, and, if clinically indicated,
bone scans and cranial magnetic resonance imaging were performed in all
cases. PET–CT scans were performed as part of the prospective studies
used to assess the utility of PET–CT scanning in diagnosing or staging tu-
mors. The positive findings on PET–CT and CT scans were labeled to iden-
tify the involved lymph node station. Definitive diagnosis was established
based on the histopathologic findings of lymph node sampling in mediasti-
noscopy or biopsy during the surgical procedure. If a mediastinoscopy was
performed, histologic evaluation of the specimens was performed with a fro-
zen section. If N2 disease was present, definitive resection was not per-
formed at that time. These patients received neoadjuvant therapy.
Patients with resectable disease on mediastinoscopy underwent further
operative procedures. Three patients underwent transcarinal sleeve pneumo-
nectomy, 16 underwent pneumonectomy (invasion of the left atrium, main
pulmonary artery, carina, distal trachea, and proximal main bronchus, with
some major fissure invasion), 4 underwent bilobectomy, 2 underwent sleeve
lobectomy, and 46 underwent lobectomy. One patient was identified as un-
resectable (M1) during thoracotomy. Six patients did not undergo thoracot-
omy because of positive results on mediastinoscopy. One patient given
a positive diagnosis after mediastinoscopy underwent resection as a result
of drainage to the pleural space caused by tumor necrosis and hemoptysis.
Multistation nodal mediastinal sampling was performed, with removal of
levels 2, 4, 7, 8, and 9 on the right side. For left-sided tumors, lymph nodes
at levels 5 and 6 were dissected also. However, nonpalpable station 2L could
not be removed in some patients. Hilar lymph nodes were also dissected.
Preoperative staging of the mediastinum with PET–CT scanning was
compared with conventional preoperative staging with chest CT scanning;
the accuracy of each study was assessed against the pathology results ob-
tained by means of mediastinoscopy or MLN dissection at the time of tho-
racotomy. All patients underwent tissue sampling of MLNs to compare
sampling results with imaging results.
Thoracic CT Scanning
CT examinations were performed by using a helical CT scanner (Brilliance
6; Philips Medical Systems, Cleveland, Ohio). Images (7.5 mm thick) wereThe Journal of Thoracic and Caobtained with sections after intravenous injection of 60 to 100 mL of contrast
material (Ultravist 300; Bayer Schering Pharma, Berlin, Germany). The im-
ages were read by a radiologist before obtaining a PET–CT scan. The CT
scan reader was blinded to the results of the reference tests. MLNs were con-
sidered positive if they were larger than 10 mm in their short-axis diameters.
PET–CT Scanning
Whole-body PET–CT scanning was performed with Siemens Biograph 2
PET-CT system (Siemens, Munich, Germany). A whole-body acquisition
was performed immediately 1 hour after intravenous administration of
FDG (11–16 mCi), and images were obtained from the vertex to the upper
thigh region. High-quality images were acquired, and semiquantitative mea-
surements of glucose metabolism were obtained. All patients fasted for at
least 4 hours before imaging, their fasting blood glucose levels were within
the normal range, and none received insulin to return blood glucose to nor-
mal levels. The standardized uptake values (SUVs) of hilar lymph nodes and
MLNs were determined from the transverse views by the nuclear medicine
physician blinded to results of reference tests. Coronal–sagittal images and
their correlation with CT scans were used when the exact location was un-
certain. Regions of interest were drawn on the images, and semiquantitative
SUV measurements were defined as the regional tissue radioactivity con-
centration normalized for injected dose and body weight. Results of PET–
CT scans were considered positive in the mediastinum and hilar area that
was separate from the primary mass if the SUV in patients suspected to
have lymph node metastases was greater than 2.5.
Mediastinoscopy
Mediastinoscopy was performed according to the following criteria: (1)
ipsilateral or contralateral MLNs with a diameter of greater than 10 mm in
the short axis on the chest CT scan; (2) MLN uptake on the PET–CT scan;
(3) a histopathology of adenocarcinoma on bronchoscopy or transthoracic
biopsy; (4) central tumors (tumor involving hilar structures, such as the
main bronchus, distal trachea, and main pulmonary artery; visible by means
of bronchoscopy; or both), even if N2 disease was not detected in radiologic
examinations; and (5) high-risk surgical candidacy. Mediastinoscopy was
not performed in patients excluded from these criteria or found to have
N2 disease by means of transbronchial fine-needle aspiration.
In mediastinoscopy biopsy specimens were taken from nodal stations,
with 4L, 4R, and 7 being the most commonly sampled. All lymph node
stations observed on PET–CT scans were sampled by means of medias-
tinoscopy. Video-assisted thoracoscopy was performed in patients with
positivity of lymph nodes at station 5, as well when the cervical medias-
tinoscopy result was negative. In patients with clinical stage I or II NSCLC
and without the above criteria based on PET–CT and CT scanning, medias-
tinoscopy was not performed, but multinodal mediastinal sampling at the
time of thoracotomy was performed.
If metastasis of NSCLC to the MLNs was detected at the time of media-
stinoscopy, then lung resection was not performed, and patients were
referred to neoadjuvant therapy. If the MLNs were negative for metastasis,
we continued the procedure with thoracotomy and resection with mediasti-
nal lymphadenectomy.
Statistical Analysis
CT and PET–CT findings were compared with histopathologic findings
in the lymph node stations undergoing biopsy, resection, or both to deter-
mine their diagnostic capabilities. The diagnostic efficacy of the CT and
PET–CT scans was calculated with sensitivity, specificity, positive and neg-
ative predictive values, and accuracy. True positivity and true negativity
were assessed based on the presence of N2 disease in patients with NSCLC.
RESULTS
There were 73 male and 5 female patients (age range, 44–
79 years; mean age, 61.3 years) in the study.rdiovascular Surgery c Volume 138, Number 5 1201
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STABLE 1. Sensitivity, specificity, PPV, NPV, and accuracy of MLN metastases on PET–CT and CT scanning of patients with NSCLC
Sensitivity (TP/TPþFN) Specificity (TN/TNþFP) PPV (TP/TPþFP) NPV (TN/TNþFN) Accuracy (TPþTN/total)
PET–CT 81.8% 89.5% 56.2% 96.7% 88.4%
CT 45.4% 80.5% 27.7% 90% 75.6%
PPV, Positive predictive value; NPV, negative predictive value; MLN, mediastinal lymph node; PET, positron emission tomography; CT, Computed tomography; NSCLC, non–
small cell lung cancer; TP, true-positive; FN, false-negative; TN, true-negative; FP, false-positive.Histopathology
Final histology was available on 397 lymph node stations
(265 N2 tumors from 78 patients, 107 hilar tumors from 71
patients, and 25 N3 tumors from 33 patients) sampled during
mediastinoscopy or surgical intervention. The specific
histologic subtypes included adenocarcinoma (n ¼ 16),
epidermoid carcinoma (n ¼ 41), adenosquamous carcinoma
(n ¼ 5), and large cell or undifferentiated carcinoma (n ¼
16). Pathologic stages of the patients were as follows: 5 stage
IA, 20 stage IB, 1 stage IIA, 16 stage IIB, 16 stage IIIA, 16
stage IIIB, and 4 stage IV cases. One of the patients with
stage IV disease did not undergo resection because of a nod-
ule identified in the lesion-free lobe during the operation,
and 3 other patients with solitary brain metastasis or adrenal
metastasis underwent resections.
Thoracic CT Scanning
All patients underwent chest CT and PET–CT scanning,
and the results were compared with the histologic sampling
results of mediastinoscopy, mediastinal lymphadenectomy,
or both. Comparison of the results of CT scanning and defin-
itive histopathology revealed true-positive (n¼ 5), true-neg-
ative (n ¼ 54), false-negative (n ¼ 6), and false-positive
(n ¼ 13) results. Enlarged MLNs on CT scans were found
in 18 patients, but only 5 of them had N2 disease at patho-
logic staging. Sixty patients did not have enlarged MLNs;
unexpected N2 disease was found in 6 of them. Of the 11
patients with N2 disease, CT scanning correctly identified
only 5 (45.4%). Sensitivity, specificity, and positive and neg-
ative predictive values of N2 involvement in thoracic CT scan-
ning were 45.4%, 80.5%, 27.7%, and 90%, respectively.
The accuracy of CT scanning was 75.6% (Table 1).
PET–CT Scanning
PET-CT scanning correctly staged disease in 69 (88.4%)
of 78 patients in our study. In patients with FDG uptake into
the mediastinum, the presence of N2 disease in 9 of 16
positive PET–CT scans was confirmed by means of media-
stinoscopy, surgical intervention, or both. There were 2
false-negative PET–CT scan results among 11 patients
with proved N2 disease. In 62 patients there was no suspi-
cion of MLNs on the PET scans; 2 of these patients had
MLNs at pathologic staging. Seven of 16 patients having up-
take in MLNs on PET–CT scanning had false-positive
results. In 1 of these patients, histopathologic examination
revealed lymph node tuberculosis. The characteristics of1202 The Journal of Thoracic and Cardiovascular Suthese patients are presented in Table 2. Thus the sensitivity,
specificity, and positive and negative predictive values of
MLN involvement in PET–CT scanning were 81.8%,
89.5%, 56.2%, and 96.7%, respectively (Table 1).
McNemar’s test performed between CT and PET–CT scans
did not yield statistically significant results (P> .05).
Because of the importance of identifying patients with
stage IIIA disease properly before lung resection, the records
of 2 patients with PET–CT scans that were false-negative
for the MLNs were reviewed. These 2 patients underwent
surgical resection with mediastinal lymphadenectomy. In
pathologic evaluations both patients had metastasis in a para-
esophageal lymph node (station 8) and in a single station.
These 2 patients had stage T2 epidermoid carcinoma, with
1 nodal station positive for metastatic disease (Table 3).
One of the patients had a right hilar and the other had
a left lower lobe tumor. The first had mediastinoscopy,
with negative results when thoracotomy/pneumonectomy
(because of fissural invasion) was performed. The other pa-
tient directly had thoracotomy/lobectomy.
There was 52 true-negative, 1 false-negative, 5 true-posi-
tive, and 2 false-positive results among 60 patients who had
no lymph node enlargement on CT scans, whereas 8 true-
negative, 1 false-negative, 4 true-positive, and 5 false-posi-
tive results were found in patients with PET–CT scans who
had enlarged lymph nodes on CT scans.
Involvement of hilar lymph nodes was assessed in 71 pa-
tients after excluding 6 patients identified as having MLN in-
volvement, who were not sent for surgical intervention, as
well as 1 patient identified as being unresectable during sur-
gical intervention. On PET–CT scanning, uptake in hilar
lymph nodes was detected in 14 patients. Five of these pa-
tients had false-positive results. Thirty-nine patients did
TABLE 2. False-positive PET–CT findings of MLNs in patients with
NSCLC
Patient no. Age/sex Cell type Station
Primary
tumor stage
1 72/M Epidermoid Carcinoma 4L T2
2 57/M Epidermoid Carcinoma 4L T2
3 68/M Epidermoid Carcinoma 4R and 7 T2
4 50/M Adenocarcinoma 3 T3
5 65/M Epidermoid Carcinoma 4L T3
6 69/M Epidermoid Carcinoma 5 T3
7 66/M Epidermoid Carcinoma 4L T2
PET, Positron emission tomography; CT, Computed tomography; NSCLC, non–small
cell lung cancer; M, male.rgery c November 2009
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negative results. Thus sensitivity, specificity, and positive
and negative predictive values of hilar lymph node involve-
ment in PET–CT scans were 34.6%, 88.8%, 64.2% and
70.1%, respectively. The accuracy was calculated as 69%
(Table 4).
When hilar lymph node and MLN evaluations based on
PET–CT scans were compared with results after resection
with mediastinoscopic biopsy, thoracotomy, or both, 16
cases were upstaged (false-negative 2 cases intersected in me-
diastinal and hilar lymph node assessment), 12 patients were
downstaged, and 50 patients remained with the same stage.
Mediastinoscopy
Mediastinoscopy was performed in 33 of the 78 study pa-
tients. The mean lymph node station number per patient after
mediastinoscopy was 3.12 0.78 and that after thoracotomy
was 1.51  0.53 and 3.38  1.45 for hilar lymph nodes and
MLNs, respectively. Mediastinoscopic frozen sections were
negative for metastatic disease in 26 patients, who then
went on to thoracotomy according to our previous study.5
One patient with negative results for frozen section specimens
after mediastinoscopy underwent resection, and definitive
histopathologic examination of the same sections was posi-
tive. This patient was evaluated as having a false-negative re-
sult in mediastinoscopic frozen section examination. Seven
patients had stage N2 disease diagnosed by means of media-
stinoscopy/thoracoscopy. Six of these were referred to neoad-
juvant therapy. One had resection as a result of tumor necrosis
and hemorrhage. Two patients were identified as having pos-
itive results for station 5 in PET–CT scans and underwent
video-assisted thoracoscopy; one of these went to resection
with negative results, and the other was referred to neoadju-
vant treatment with positive results. In our study, no N3
disease was found in patients who underwent mediastino-
scopy. Mediastinoscopy was 96.9% accurate (1 false-nega-
tive result) because the results of the positive frozen
sections were confirmed by final pathology, and the results
of the negative mediastinoscopy findings were confirmed
by mediastinal lymphadenectomy during thoracotomy.
DISCUSSION
We observed that PET–CT scanning has high reliability in
excluding N2 disease, and mediastinoscopy might not be
performed in cases with PET–CT scanning–negative MLNs.
TABLE 3. False-negative PET–CT findings of MLNs in patients with
NSCLC
Patient no. Age/sex Cell type Station
Primary
tumor stage
1 71/M Epidermoid Carcinoma 8 T2
2 59/F Epidermoid Carcinoma 8 T2
PET, Positron emission tomography; CT, Computed tomography; MLNs, mediastinal
lymph nodes; NSCLC, non–small cell lung cancer; M, male; F, female.The Journal of Thoracic and CaHellwig and coworkers6 stated that the choice of an SUV
of 2.5 as the threshold is justified for mediastinal staging
because false-negative results plus false-positive results is
minimized. The resulting high negative predictive value of
96% allows the omission of mediastinoscopy in patients
with negative mediastinal findings on FDG–PET images.
However, Bryant and colleagues7 have used an SUV of
5.3 instead of the traditional value of 2.5, and the accuracy
of integrated PET–CT scanning for each N2 nodal station
has been maximized and at least 92% for each. We used
the 2.5 cutoff rate as a positive PET–CT result for the medi-
astinal and hilar lymph nodes. We do not have enough pa-
tients for evaluating different SUV cutoff rates.
In predicting the mediastinal contents, PET scanning is
reported to be superior to CT scanning. In a meta-analysis
including 40 studies, the sensitivity and specificity were
reported as 85% and 90% for PET–CT scanning versus
61% and 79% for CT scanning, respectively.8 In a study
by Gupta and associates,4 the sensitivity, specificity, and ac-
curacy of PET scanning in identifying MLNs was reported
as 87%, 91%, and 82%, respectively, and corresponding
values for CT scanning were 68%, 61%, and 63%.
It is possible to decrease false-negative and false-positive
results by combining PET and CT scanning in identifying
metastatic lymph nodes. Weng and coworkers9 reported
that to contribute to each other, imaging methods should
be used together and that this should reveal better results
for sensitivity, specificity, and accuracy (82%, 96%, and
91%, respectively) and that be more accurate in the staging
of mediastinal disease. Cerfolio and colleagues10 reported
that in the evaluation of N2 disease, PET–CT scanning
was more accurate than PET scanning alone (96% vs
93%). A study by Kelly and associates3 concluded that add-
ing PET scanning to CT scanning used for clinical staging of
patients with NSCLC would improve the identification
of N2 disease in the preoperative period. When the results
of PET and CT scanning were combined in this study, sen-
sitivity, specificity, and accuracy rates were improved (70%,
98%, and 91%, respectively). In our study the results for
MLN staging by means of PET-CT scanning were superior
to those for CT scanning. The sensitivity, specificity, and
positive and negative predictive values of MLN involvement
in PET–CT scanning were 81.8%, 89.5%, 56.2%, and
96.7%, and these values in thoracic CT scanning were
45.4%, 80.5%, 27.7%, and 90%, respectively. Mediastino-
scopic biopsy or surgical resection was taken as the basis for
TABLE 4. Sensitivity, specificity, PPV, NPV, and accuracy of hilar
lymph node metastases on PET–CT scanning in patients with NSCLC
Sensitivity Specificity PPV NPV Accuracy
PET–CT 34.6% 88.8% 64.2% 70.1% 69%
PPV, Positive predictive value; NPV, negative predictive value; PET, positron emis-
sion tomography; CT, computed tomography; NSCLC, non–small cell lung cancer.rdiovascular Surgery c Volume 138, Number 5 1203
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in patients with negative lymph nodes as shown by CT and
PET-CT scanning can be comprehended as a verification
bias. However, in 91% of the cases, lymph node evaluation
was performed histopathologically on those nodes resected
surgically without taking mediastinoscopy into consider-
ation. For this reason, we think that bias is not an issue in
the analysis of our data.
Gould and colleagues8 reported that PET scanning was
more sensitive but less specific when CT scanning showed
enlarged lymph nodes than when CT scanning showed no
lymph node enlargement. We found 1 false-negative and 8
true-negative results in patients who had lymph node en-
largement on CT scanning with the evaluation of PET–CT
scanning. The sensitivity and specificity of PET–CT scan-
ning in our patients with enlarged lymph nodes on CT scan-
ning was 80% and 61.5%, respectively, whereas the values
were 83.3% and 96.2% in patients who had no lymph node
enlargement. Because of the poor adjunct of PET–CT scan-
ning, in patients with enlarged lymph nodes on CT scanning,
mediastinoscopy can be considered as a first alternative for
mediastinal staging. With the consideration of intelligible
spending of the resources allocated to health, in patients
who had N0 disease mediastinoscopically, the use of PET
scanning can be limited to demonstrating distant metastases.
Kelly and associates3 found lower PET scanning sensitiv-
ity rates than those reported in the literature, especially for
patients with adenocarcinoma (62%). Four of 5 patients
having false-negative PET scan results for mediastinal eval-
uation had adenocarcinoma as the histologic type. Patients
with false-negative lymph node results on PET scanning
can end in incomplete resection if the surgeon abides by clin-
ical staging. In our study the number of patients with false-
negative results on mediastinal evaluation with PET–CT
scanning was very low and limited to 2. Both of these pa-
tients had epidermoid carcinoma, involvement was at station
8, and there was a single involvement. Because it is not pos-
sible to reach this station with mediastinoscopy, in one of
these patients N2 disease could not be diagnosed with me-
diastinoscopy. Endoscopic ultrasound-guided fine-needle
aspiration (EUS–FNA) is a minimally invasive technique
used for staging of lung cancer and allows reaching the
lymph node stations numbered 7 and 8 and especially 9,
which cannot be approached easily by using standard media-
stinoscopy.11 According to Eloubeidi and coworkers,12
EUS–FNA is more accurate (92.5%) and has a higher pos-
itive predictive value (100%) than PET scanning for poste-
rior MLNs. DeLeyn and associates,13 on the other hand,
stated that endobronchial ultrasound-guided fine-needle as-
piration (EBUS–FNA) and EUS-FNA have high specific-
ities but low negative predictive values; therefore in
patients with negative results obtained with these tech-
niques, invasive surgical techniques are indicated. We did
not use EUS–FNA and EBUS–FNA because they were1204 The Journal of Thoracic and Cardiovascular Sunot available in our hospital. In patients undergoing neoad-
juvant treatment, remediastinoscopy is recommended to
evaluate the response to treatment, despite it being techni-
cally more challenging than the initial procedure. In our clin-
ical practice we make use of remediastinoscopy for
mediastinal staging after neoadjuvant treatment. However,
we did not include patients receiving neoadjuvant treatment
in this study. For restaging the mediastinum, as an alterna-
tive to this technique, EBUS–FNA and EUS–FNA are rec-
ommended as invasive tests yielding similar results to
video-assisted thoracoscopic surgery and remediastino-
scopy.13 In a series of 124 patients receiving neoadjuvant
treatment for N2 disease and undergoing mediastinal restag-
ing with EBUS–FNA, the specificity was high, but the neg-
ative predictive value was low (20%), and negative tumor
findings had to be confirmed with surgical staging.14
If clinical staging is taken as the basis, patients with false-
positive MLN results can receive unnecessary chemother-
apy before curative surgical intervention. In our study 13
patients with enlarged lymph nodes on CT scanning were
evaluated as having false-positive results, and 5 of these
patients had lymph node abnormality with false-positive
enhancement on PET–CT scanning. Two other patients
identified as having false-positive results on PET–CT scan-
ning were found to have lesions smaller than 10 mm on CT
scanning. All of these patients were evaluated with mediasti-
noscopy, and they were identified as having negative results
for N2 disease (1 patient was further examined with video-
assisted thoracoscopy) and underwent resection. Of 7
patients identified as having false-positive results on PET–
CT scanning, 6 had epidermoid carcinoma as the cellular
type. In 4 of these patients, the primary tumor was pT2,
and in the remaining 3 patients, it was pT3. There are publi-
cations claiming that false-positive appearance of lymph
nodes in PET scanning can be due to inflammatory or gran-
ulomatous processes.15,16 In our study of patients with false-
positive results on PET–CT scanning, only 1 was identified
to have tuberculosis, and in the remaining patients, histo-
pathologic examination of the lymph nodes was reported
as a reactive change.
With PET scanning, it can be difficult to localize the
lymph nodes in the hilar region and to differentiate them
from MLNs. Scott and associates17 made a retrospective
analysis of 25 patients with potentially operable NSCLC
evaluated for N2 disease with PET scanning and found
that extensive hilar metastases were wrongly classified as
mediastinal because of their proximity to the mediastinum.
To surmount this problem, Cerfolio and colleagues10 used
PET–CT scanning to evaluate hilar lymph nodes and had
significantly better results compared with those obtained
with PET scanning alone. In their PET–CT evaluation, sen-
sitivity, specificity, and positive and negative predictive
values were 94%, 89%, 43%, and 99% respectively.
With the PET–CT scanning used in our study, it wasrgery c November 2009
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lar false negativity was high (17/71) and other parameters
were low, including sensitivity (34.6%).
A relatively small number of patients is the limitation of
this study. However, we concluded that PET–CT scanning
yields better results than CT scanning. Negative appearances
of MLNs in PET–CT scanning results in high success in pre-
dicting the mediastinal content; in positive appearances the
success of prediction is limited. Therefore there is the need
for mediastinoscopy in PET–CT scanning–positive MLNs,
but it might not be necessary for PET–CT scanning–negative
lymph nodes.
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